Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a Phase 3 study, and now plans …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

FDA's Peter Marks resigns, saying he won't accept Kennedy's 'misinformation and lies'

Bluebird gets new M&A bid, seeking to top private equity offer

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

European regulator rejects Lilly's Alzheimer’s drug over potentially fatal side effects

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

FDA approves Sanofi's RNAi drug for hemophilia A and B

Chica­go biotech Emalex says it cleared a Phase 3 for Tourette syn­drome, will seek FDA ap­proval

Senior Reporter

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Chicago biotech Emalex says it cleared a Phase 3 for Tourette syndrome, will seek FDA approval